Centre National De La Recherche Scientifique

Institut National De La Sante Et De La Recherche Medicale

Université De Nantes

Nantes Université

Ogd2 Pharma

Institut De Cancerologie De L'ouest

Stéphane Birkle

Jean-Marc Le Doussal

Brigitte Assouline

Denis Cochonneau

Jacques Barbet

Jean-Marie Mussini

Jacques Aubry

Jean-Francois Chatal

Mickaël Terme

Sébastien Faraj

Julien Fleurence

Mylène Dorvillius

Assia Mezazigh Hami

Jean-François Chatal

Stéphane Supiot

Disclosed is a method for delivery of an anti-cancer agent into a cell expressing the OAcGD2 ganglioside by using an antibody recognizing the OAcGD2 ganglioside.

Use of antibody against O-acetylated GD2 ganglioside to improve the therapeutic potential of drugs

The invention relates to the use of monoclonal antibodies that only recognise the O-acetylated form of the GD2 ganglioside, or fragments of said antibody, for the diagnosis and the treatment of cancers in which the cells express the O-acetylated GD2, said antibody or said fragment recognising the O-acetylated GD2 molecules expressed by the tumoral cells and not recognising the GD2 molecules expressed at the surface of the peripheral nerves, in order to increase the specificity of the diagnosis and reduce the toxicity of the treatments. The invention also relates to artificially modified antibodies advantageously used for treating and diagnosing cancers in which the cells express the O-acetylated GD2.

Use of monoclonal antibodies specific to the O-acetylated form of GD2 ganglioside for treatment of certain cancers

Growing community of inventors

Nantes, France

Stéphane Birkle